Karyopharm Expanded Access Program for Selinexor
Sponsor: Karyopharm Therapeutics Inc
ClinicalTrials ID:NCT07215832
The Karyopharm Expanded Access Program provides selinexor to patients who have exhausted all other treatment options and do not qualify for ongoing clinical trials. Access is granted through treating physicians who secure necessary regulatory approvals. Selinexor, an investigational drug, is administered under strict safety-reporting regulations. Eligibility criteria are not specified.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
KEAP is an expanded access program designed to provide selinexor to eligible participants outside of a clinical trial before the drug has been given marketing approval by the country's regulatory agency or the drug is commercially available in the country. Patients who do not qualify for an ongoing clinical trial but who might benefit from the investigational medicine may be eligible, provided they have exhausted all other available treatment options. Investigational medicines are provided to patients only through treating physicians who obtain the relevant approval on behalf of their patient from the relevant regulatory agency and follow all applicable safety-reporting regulations of the respective country.
Eligibility Criteria
Inclusion Criteria
-
Exclusion Criteria
-
Get This Program In Your Inbox
You can sign up and apply your patients for this program.